glp·helper
glphelper.com/ozempic/nevada/reno
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Reno, NV

Verified Ozempic providers in Reno, NV. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
36
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Nevada
36 of 36 shown

Find an Ozempic provider in Nevada.

Every entry is checked against the NPI registry and the Nevada medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Nevada city · /ozempic/nevada/{city}
§ 03Getting Ozempic in Nevada
36 providers · 3 metros

How a prescription works in Nevada.

You don’t have to leave Nevada to start. Because semaglutide isn't a controlled substance, a Nevada-licensed prescriber can evaluate you by telehealth and send the script to a pharmacy near you, or you can see one of the 36 local providers below in person. What you pay depends on your plan, not your zip code.

Telehealth
Available in Nevada
Ozempic (semaglutide) is a GLP-1, not a controlled substance, so a Nevada-licensed clinician can assess you and prescribe over video, with no federal in-person-visit requirement.
Who can prescribe
NV-licensed clinicians
Any physician, nurse practitioner, or PA licensed in Nevada can prescribe Ozempic. The 36 providers below are checked against the NPI registry and the Nevada board.
Medicaid (weight loss)
Diabetes only
As of April 2026, Nevada Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Nevada’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Nevada

Diagnosed diabetes reaches 10.8% of adults in Nevada.

of Nevada adults have obesity
34.2%
diagnosed diabetes
10.8%

Age-adjusted estimates for Nevada, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossOzempic side effects in men
§ 05Support around Ozempic in Reno
6 dietitians

The prescription is one part. Here is the rest, in Reno.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Reno, NV, ordered as the registry lists them, never by who pays us.

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Jana Ailes, RD, LD
RD
Registered dietitian · Renal
670 Sierra Rose Dr
Call 775-322-4550NPI 1033622253
Lynice Anderson, Rd, CDE
RD
Registered dietitian
850 Mill St
Call 775-982-3948NPI 1568616712
Kelcie Atkin, RD, LD
RD
Registered dietitian
10085 Double R Blvd Ste 325
Call 775-982-5073NPI 1659769172
Katherine Ault, RD
RD
Registered dietitian
580 W 5Th St
Call 775-786-4673NPI 1356534887
Cynthia Barrett
RD
Registered dietitian
1000 Locust St
Call 775-328-1203NPI 1225054570
Emily Barrett, RD
RD
Registered dietitian
10085 Double R Blvd Ste 325
Call 775-982-5073NPI 1487203824

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Stacy Briscoe, M.S., R.D
NUTRITIONIST
Nutritionist · Education
75 Pringle Way Ste 505
Call 775-982-5262NPI 1225360936
Linda Lindenmuth, PhD, CNC
NUTRITIONIST
Nutritionist
1104 California Ave
Call 775-322-4372NPI 1164859328
Jaimee Maranon, MS, NDTR
NUTRITIONIST
Nutritionist
9624 Glen Ridge Dr
Call 775-338-5897NPI 1477238558
Lindsay Mccue, CHHC
NUTRITIONIST
Nutritionist
1005 Terminal Way Ste 220
Call 775-505-4917NPI 1053921247
Carly Neubert, NC
NUTRITIONIST
Nutritionist · Education
8985 Double Diamond Pkwy # B8Na
Call 805-354-8061NPI 1972870137
Kimberly Sorensen
NUTRITIONIST
Nutritionist · Education
3354 Forest View Ln
Call 760-274-4680NPI 1487581153
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in Nevada

NPI-verified Ozempic (semaglutide) prescribers and clinics, ordered by availability, never by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in Nevada

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]